OTC Markets OTCPK - Delayed Quote USD

Pharming Group N.V. (PHGUF)

Compare
0.8230 0.0000 (0.00%)
At close: October 21 at 4:00 PM EDT
Loading Chart for PHGUF
DELL
  • Previous Close 0.0000
  • Open 0.8270
  • Bid 0.8747 x 312700
  • Ask 0.9500 x 306000
  • Day's Range 0.8270 - 0.8270
  • 52 Week Range 0.7500 - 1.2900
  • Volume 1,000
  • Avg. Volume 873
  • Market Cap (intraday) 586.235M
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date Oct 24, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 34.00

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

www.pharming.com

382

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PHGUF

View More

Performance Overview: PHGUF

Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHGUF
29.96%
AEX-Index
14.17%

1-Year Return

PHGUF
27.81%
AEX-Index
25.42%

3-Year Return

PHGUF
11.70%
AEX-Index
11.53%

5-Year Return

PHGUF
34.16%
AEX-Index
56.85%

Compare To: PHGUF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHGUF

View More

Valuation Measures

Annual
As of 10/21/2024
  • Market Cap

    598.38M

  • Enterprise Value

    560.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.24

  • Price/Book (mrq)

    2.53

  • Enterprise Value/Revenue

    2.02

  • Enterprise Value/EBITDA

    77.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.80%

  • Return on Assets (ttm)

    -1.73%

  • Return on Equity (ttm)

    -6.33%

  • Revenue (ttm)

    277.56M

  • Net Income Avi to Common (ttm)

    -13.32M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    160.32M

  • Total Debt/Equity (mrq)

    55.23%

  • Levered Free Cash Flow (ttm)

    -292k

Research Analysis: PHGUF

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 74.09M
Earnings -1.22M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

31.00
34.00 Average
0.8230 Current
37.00 High
 

Company Insights: PHGUF

People Also Watch